Functional Assessment of Chronic Illness Therapy Measurement System (FACIT)

Cella D


Basic description

Developed in 1987

Composed of a generic CORE questionnaire, the Functional Assessment of Cancer Therapy-General FACT-G, complemented with FACIT scales addressing relevant disease-, treatment-, or condition-related issues not covered in the general questionnaire.

There are over 40 different FACIT scales with a unique name and acronym corresponding to the targeted issue, and nine symptom indices available for select tumor sites.

The Trial Outcome Index can be computed for any FACIT disease-, treatment-, or condition-specific scale. It is the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and "additional concerns" subscales. The TOI is an efficient summary index of physical/functional outcomes. It is a common endpoint used in clinical trials.

Cancer-specific measures described in PROQOLID:

Lung cancer: FACT-Lung

Hepatobiliary cancer: FACT-Hep

Breast cancer: FACT-B

Prostate cancer: FACT-P

Treatment-specific measures described in PROQOLID:

For patients receiving Biologic Response Modifiers: FACT-BRM

Symptom-specific measures described in PROQOLID:

Fatigue: FACIT-F and FACIT-Fatigue

For patients with Anemia/Fatigue: FACT-An

Non-Cancer specific measure described in PROQOLID:

Functional Assessment of Multiple Sclerosis: FAMS


Cella D

Copyright 1987, 1997
To measure health-related quality of life of people with chronic illnesses
Therapeutic area
  • Pathological Conditions, Signs and Symptoms
  • Neoplasms
and other chronic illness
Therapeutic indication
  • Chronic Diseases
  • Generic for Neoplasms
- Cancer specific measures: breast; bladder; brain; colon; central nervous system; cervical; esophageal; endometrial; gactric, head & neck; hepatobiliary; leukemia; lung; leukemia, lymphoma; melanoma, ovarian; prostate, vulva,
- Cancer specific-symptom indices: breast, bladder, brain, colon, head & neck, lung, lymphoma, hepatobiliary, kidney, ovarian, prostate
- Treatment-specific measures: bone marrow transplantation; biologic response modifiers; neurotoxicity; taxane therapy
- Symptom-specific measures: anorexia/cachexia; diarrhea; anemia/fatigue; endocrine symptoms; lymphedema; neutropenia; thrombocytopenia; bone pain, fecal incontinence; urinary incontinence
- Non cancer specific measures: palliative care; spiritual well-being; HIV infection; multiple sclerosis; treatment satisfaction
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
1 translation(s)
Bibliographic reference(s) of the original questionnaire

Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: Development and validation of the general measure. Journal of Clinical Oncology 1993, 11(3), 570-579 (PubMed abstract)
Webster, K., Odom, L., Peterman, A., Lent, L., Cella, D. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Quality of Life Research 1999, 8(7):604